BLAINTRAVITREALINJECTABLEPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VABYSMO (faricimab) is a bispecific antibody (BSAB) administered as an intravitreal injection for retinal diseases. It is a dual antagonist of angiopoietin-2 and VEGF-A, designed to address both vascular instability and abnormal angiogenesis. The mechanism targets pathways implicated in diabetic macular edema and retinal vein occlusion.
$15MPart D
PeakVABYSMO is in peak commercial phase with modest uptake in 2023; the brand team is likely stable or modestly expanding given market penetration is still establishing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Started Dec 2026
50 enrolled
Central Serous Chorioretinopathy (CSC)
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
Started Jul 2026
25 enrolled
Presumed Ocular Histoplasmosis
Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material
Started May 2026
100 enrolled
Macular Degeneration, Age Related
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
Started Aug 2025
120 enrolled
Polypoidal Choroidal Vasculopathy
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Started Aug 2025
426 enrolled
Proliferative Diabetic Retinopathy (PDR)
Worked on VABYSMO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.